Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia

Translocation t(6;11) occurs in approximately 5% of patients with acute myeloid leukemia (AML) corresponding to 11q23/mixed lineage leukemia (MLL) rearrangement. The AF6 gene on chromosome 6q27 is the fusion partner of the MLL gene on 11q23 in t(6;11), which results in a poor prognosis. The case of...

Descripción completa

Detalles Bibliográficos
Autores principales: Edahiro, Taro, Ureshino, Hiroshi, Chishaki, Ren, Fujino, Keita, Mino, Tatsuji, Yoshida, Tetsumi, Fukushima, Noriyasu, Ichinohe, Tatsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928651/
https://www.ncbi.nlm.nih.gov/pubmed/36819153
http://dx.doi.org/10.1002/jha2.630
_version_ 1784888688837132288
author Edahiro, Taro
Ureshino, Hiroshi
Chishaki, Ren
Fujino, Keita
Mino, Tatsuji
Yoshida, Tetsumi
Fukushima, Noriyasu
Ichinohe, Tatsuo
author_facet Edahiro, Taro
Ureshino, Hiroshi
Chishaki, Ren
Fujino, Keita
Mino, Tatsuji
Yoshida, Tetsumi
Fukushima, Noriyasu
Ichinohe, Tatsuo
author_sort Edahiro, Taro
collection PubMed
description Translocation t(6;11) occurs in approximately 5% of patients with acute myeloid leukemia (AML) corresponding to 11q23/mixed lineage leukemia (MLL) rearrangement. The AF6 gene on chromosome 6q27 is the fusion partner of the MLL gene on 11q23 in t(6;11), which results in a poor prognosis. The case of a patient with 11q23/MLL‐rearranged AML who successfully underwent a third allogeneic stem cell transplantation after treatment with azacitidine (AZA) and venetoclax (VEN) is presented in this article. This report suggests that a combination of AZA and VEN is an effective therapeutic approach for relapsed and refractory MLL‐rearranged AML.
format Online
Article
Text
id pubmed-9928651
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-99286512023-02-16 Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia Edahiro, Taro Ureshino, Hiroshi Chishaki, Ren Fujino, Keita Mino, Tatsuji Yoshida, Tetsumi Fukushima, Noriyasu Ichinohe, Tatsuo EJHaem Case Reports Translocation t(6;11) occurs in approximately 5% of patients with acute myeloid leukemia (AML) corresponding to 11q23/mixed lineage leukemia (MLL) rearrangement. The AF6 gene on chromosome 6q27 is the fusion partner of the MLL gene on 11q23 in t(6;11), which results in a poor prognosis. The case of a patient with 11q23/MLL‐rearranged AML who successfully underwent a third allogeneic stem cell transplantation after treatment with azacitidine (AZA) and venetoclax (VEN) is presented in this article. This report suggests that a combination of AZA and VEN is an effective therapeutic approach for relapsed and refractory MLL‐rearranged AML. John Wiley and Sons Inc. 2022-12-26 /pmc/articles/PMC9928651/ /pubmed/36819153 http://dx.doi.org/10.1002/jha2.630 Text en © 2022 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Edahiro, Taro
Ureshino, Hiroshi
Chishaki, Ren
Fujino, Keita
Mino, Tatsuji
Yoshida, Tetsumi
Fukushima, Noriyasu
Ichinohe, Tatsuo
Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia
title Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia
title_full Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia
title_fullStr Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia
title_full_unstemmed Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia
title_short Successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/MLL‐rearranged complex karyotype acute myeloid leukemia
title_sort successful combination treatment with azacitidine and venetoclax as a bridging therapy for third allogenic stem cell transplantation in a patient with 11q23/mll‐rearranged complex karyotype acute myeloid leukemia
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928651/
https://www.ncbi.nlm.nih.gov/pubmed/36819153
http://dx.doi.org/10.1002/jha2.630
work_keys_str_mv AT edahirotaro successfulcombinationtreatmentwithazacitidineandvenetoclaxasabridgingtherapyforthirdallogenicstemcelltransplantationinapatientwith11q23mllrearrangedcomplexkaryotypeacutemyeloidleukemia
AT ureshinohiroshi successfulcombinationtreatmentwithazacitidineandvenetoclaxasabridgingtherapyforthirdallogenicstemcelltransplantationinapatientwith11q23mllrearrangedcomplexkaryotypeacutemyeloidleukemia
AT chishakiren successfulcombinationtreatmentwithazacitidineandvenetoclaxasabridgingtherapyforthirdallogenicstemcelltransplantationinapatientwith11q23mllrearrangedcomplexkaryotypeacutemyeloidleukemia
AT fujinokeita successfulcombinationtreatmentwithazacitidineandvenetoclaxasabridgingtherapyforthirdallogenicstemcelltransplantationinapatientwith11q23mllrearrangedcomplexkaryotypeacutemyeloidleukemia
AT minotatsuji successfulcombinationtreatmentwithazacitidineandvenetoclaxasabridgingtherapyforthirdallogenicstemcelltransplantationinapatientwith11q23mllrearrangedcomplexkaryotypeacutemyeloidleukemia
AT yoshidatetsumi successfulcombinationtreatmentwithazacitidineandvenetoclaxasabridgingtherapyforthirdallogenicstemcelltransplantationinapatientwith11q23mllrearrangedcomplexkaryotypeacutemyeloidleukemia
AT fukushimanoriyasu successfulcombinationtreatmentwithazacitidineandvenetoclaxasabridgingtherapyforthirdallogenicstemcelltransplantationinapatientwith11q23mllrearrangedcomplexkaryotypeacutemyeloidleukemia
AT ichinohetatsuo successfulcombinationtreatmentwithazacitidineandvenetoclaxasabridgingtherapyforthirdallogenicstemcelltransplantationinapatientwith11q23mllrearrangedcomplexkaryotypeacutemyeloidleukemia

Ejemplares similares